X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Verici Dx Plc

Verici Dx offers three-test platform for kidney transplant risk assessment

Verici Dx has built a three-test kidney transplant platform covering pre-transplant rejection risk, post-transplant acute rejection and progressive fibrosis...
EDX Medical Group plc

EDX Medical signs three-year employee health screening deal with Arnold Clark Group

EDX Medical has entered a three-year agreement to provide health and wellbeing screening to Arnold Clark Group employees across the UK, with the contract expected to generate annual revenue of..
Oxford Nanopore Technologies plc

Oxford Nanopore wins preliminary injunction against MGI Tech

The Munich Local Division of the Unified Patent Court has granted Oxford Nanopore a preliminary injunction restricting sales and use of MGI Tech’s Cyclone Sequencing Systems across several European markets...
Physitrack plc

Physitrack clarifies its role alongside physical therapy billing software

Physitrack is positioning its platform alongside physical therapy billing software, focusing on patient engagement, rehabilitation workflows and system integration...
GSK Plc

GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

GSK has agreed to acquire global rights to Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. The programme is expected to enter..
BIOG

Biotech Growth Trust extends strong performance in 2026

Year to date, the Trust’s NAV rose 36.2% and its share price gained 44.8%, ahead of the NASDAQ Biotechnology Index return of 24.3%...
Genflow Biosciences Plc

Genflow advances SIRT6 gene therapy

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions...
PTRK

Physitrack wins three-year US healthcare contract

Physitrack has been selected as the digital rehabilitation platform for a US metropolitan safety net healthcare system, covering 86 practitioners. The three-year agreement has a potential total contract value of..
BIOG

Biotech Growth Trust stands out in a stronger biotechnology sector

Biotech Growth Trust has outpaced its biotechnology peers during a volatile market period, strengthening its position as one of the sector’s most closely watched investment trusts...
GNS

Genus reports strong FY26 profit growth, launches £60m share buyback

Genus reported a 35% rise in adjusted profit before tax for the year ended 30 June 2026, alongside stronger cash generation and reduced leverage. The company also announced a £60m..
GSK Shingrex

GSK’s Shingrix prefilled syringe approved in Japan

Japan’s health ministry has approved a ready-to-use prefilled syringe presentation of GSK’s Shingrix shingles vaccine, simplifying preparation and administration for healthcare professionals...
ONT

Oxford Nanopore to participate in September investor conferences

Oxford Nanopore will take part in the Morgan Stanley Global Healthcare Conference and RBC Capital Markets Pharma Services & Life Science Tools Virtual Conference in September, with fireside chats available..
Physitrack plc

Physitrack pushes AI deeper into physiotherapy workflows

Physitrack is integrating AI into everyday physiotherapy tasks while keeping clinical decisions under professional control...
GENF

Genflow Biosciences’ SLAB trial meets primary endpoint in aged dogs

Genflow Biosciences says its SLAB clinical trial has met its primary endpoint, with detailed results due to be presented in Toronto in October...

Physitrack selected by major US academic healthcare system for digital rehabilitation technology

Physitrack has been selected as the preferred digital rehabilitation technology provider by a large US academic healthcare system, with a proposed three-year contract worth up to approximately US$390,000. Go-live is..
AstraZeneca

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing..
BIOG

Biotech Growth Trust targets opportunity in global medical innovation

Biotech Growth Trust targets growth-stage biotechnology companies positioned around new treatments, industry consolidation and long-term healthcare demand...
Verici Dx Plc

Mayo Clinic moves transplant tolerance research towards larger clinical trials

Mayo Clinic is moving cell-based transplant tolerance research towards larger trials aimed at reducing lifelong dependence on anti-rejection drugs...
EDX Medical Group plc

EDX Medical reports diagnostic milestones and £330,000 revenue for FY2026

EDX Medical’s annual results highlight new cancer testing services, major diagnostic partnerships and £5.5 million in funding, alongside a £5.7 million full-year loss as the group continued investing in commercial..
PTRK

Physitrack Q2 2026 Shows ARR Growth, RTM Launch and Wellness Profit Recovery, Redeye

Physitrack's Q2 2026 delivered stronger ARR, Lifecare growth, a US RTM launch and renewed Wellness profitability...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Verici Dx Plc

Verici Dx offers three-test platform for kidney transplant risk assessment

Verici Dx has built a three-test kidney transplant platform covering pre-transplant rejection risk, post-transplant acute rejection and progressive fibrosis...
EDX Medical Group plc

EDX Medical signs three-year employee health screening deal with Arnold Clark Group

EDX Medical has entered a three-year agreement to provide health and wellbeing screening to Arnold Clark Group employees across the UK, with the contract expected to generate annual revenue of £1.4 million to £1.6 million...
Oxford Nanopore Technologies plc

Oxford Nanopore wins preliminary injunction against MGI Tech

The Munich Local Division of the Unified Patent Court has granted Oxford Nanopore a preliminary injunction restricting sales and use of MGI Tech’s Cyclone Sequencing Systems across several European markets...
Physitrack plc

Physitrack clarifies its role alongside physical therapy billing software

Physitrack is positioning its platform alongside physical therapy billing software, focusing on patient engagement, rehabilitation workflows and system integration...
GSK Plc

GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

GSK has agreed to acquire global rights to Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. The programme is expected to enter Phase I trials in 2027...
BIOG

Biotech Growth Trust extends strong performance in 2026

Year to date, the Trust’s NAV rose 36.2% and its share price gained 44.8%, ahead of the NASDAQ Biotechnology Index return of 24.3%...
Genflow Biosciences Plc

Genflow advances SIRT6 gene therapy

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions...
PTRK

Physitrack wins three-year US healthcare contract

Physitrack has been selected as the digital rehabilitation platform for a US metropolitan safety net healthcare system, covering 86 practitioners. The three-year agreement has a potential total contract value of approximately US$83,000, with go-live expected in Q4 2026...
BIOG

Biotech Growth Trust stands out in a stronger biotechnology sector

Biotech Growth Trust has outpaced its biotechnology peers during a volatile market period, strengthening its position as one of the sector’s most closely watched investment trusts...
GNS

Genus reports strong FY26 profit growth, launches £60m share buyback

Genus reported a 35% rise in adjusted profit before tax for the year ended 30 June 2026, alongside stronger cash generation and reduced leverage. The company also announced a £60m share buyback and said FY27 adjusted profit is expected to be in line with market expectations...
GSK Shingrex

GSK’s Shingrix prefilled syringe approved in Japan

Japan’s health ministry has approved a ready-to-use prefilled syringe presentation of GSK’s Shingrix shingles vaccine, simplifying preparation and administration for healthcare professionals...
ONT

Oxford Nanopore to participate in September investor conferences

Oxford Nanopore will take part in the Morgan Stanley Global Healthcare Conference and RBC Capital Markets Pharma Services & Life Science Tools Virtual Conference in September, with fireside chats available via webcast...
Physitrack plc

Physitrack pushes AI deeper into physiotherapy workflows

Physitrack is integrating AI into everyday physiotherapy tasks while keeping clinical decisions under professional control...
GENF

Genflow Biosciences’ SLAB trial meets primary endpoint in aged dogs

Genflow Biosciences says its SLAB clinical trial has met its primary endpoint, with detailed results due to be presented in Toronto in October...

Physitrack selected by major US academic healthcare system for digital rehabilitation technology

Physitrack has been selected as the preferred digital rehabilitation technology provider by a large US academic healthcare system, with a proposed three-year contract worth up to approximately US$390,000. Go-live is expected in late 2027, subject to completion of contracting...
AstraZeneca

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death...
BIOG

Biotech Growth Trust targets opportunity in global medical innovation

Biotech Growth Trust targets growth-stage biotechnology companies positioned around new treatments, industry consolidation and long-term healthcare demand...
Verici Dx Plc

Mayo Clinic moves transplant tolerance research towards larger clinical trials

Mayo Clinic is moving cell-based transplant tolerance research towards larger trials aimed at reducing lifelong dependence on anti-rejection drugs...
EDX Medical Group plc

EDX Medical reports diagnostic milestones and £330,000 revenue for FY2026

EDX Medical’s annual results highlight new cancer testing services, major diagnostic partnerships and £5.5 million in funding, alongside a £5.7 million full-year loss as the group continued investing in commercial growth and laboratory capabilities...
PTRK

Physitrack Q2 2026 Shows ARR Growth, RTM Launch and Wellness Profit Recovery, Redeye

Physitrack's Q2 2026 delivered stronger ARR, Lifecare growth, a US RTM launch and renewed Wellness profitability...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple